Vanda adopts limited-duration rights plan; rejects Future Pak's $7.25-$7.75/share bid

Vanda Pharmaceuticals Inc.

Board adopted a one-year stockholder rights plan effective April 17, 2024, triggered at 10% beneficial ownership.
Plan adopted in response to unsolicited proposals from Future Pak; latest offered $7.25–$7.75 per share.
Board unanimously rejected proposals as significantly undervaluing the company, citing robust pipeline and $6.75 cash per share.
Rights dividend payable to shareholders of record April 29, 2024; rights expire April 16, 2025.
Plan prevents open-market accumulation without a control premium; no shareholder action required.

item 1.01 item 3.03 item 5.03 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Vanda Pharmaceuticals Inc. entered into Rights Agreement with Equiniti Trust Company, LLC (effective 2024-04-17).

Action: entry
Counterparty: Equiniti Trust Company, LLC
Effective: 2024-04-17

Exact text from the filing

The complete terms of the Rights are set forth in a Rights Agreement (the “Rights Agreement”), dated as of April 17, 2024, between the Company and Equiniti Trust Company, LLC, a limited trust company organized under the laws of the State of New York, as rights agent.

View on SEC.gov

Browse all material agreements →

Vanda Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-099251

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.